top of page

GPCR News 

Post: Blog2_Post

Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...

July 2022


Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases


"29/06/2022

Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO). The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates. "



Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin

Kommentare